Enhancing reproducibility in cancer drug screening: how do we move forward?
about
Precision medicine for cancer with next-generation functional diagnosticsImpact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data.Amphotericin B, an Anti-Fungal Medication, Directly Increases the Cytotoxicity of NK Cells.Identifying genes that mediate anthracyline toxicity in immune cellsOptimizing sparse sequencing of single cells for highly multiplex copy number profilingThe changing 50% inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer.Transcriptome modeling and phenotypic assays for cancer precision medicine.Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance.Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.PharmacoGx: an R package for analysis of large pharmacogenomic datasets.Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration.Predictive approaches for drug combination discovery in cancer.Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing.Revisiting inconsistency in large pharmacogenomic studiesGene isoforms as expression-based biomarkers predictive of drug response in vitro.PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies.Tissue specificity of in vitro drug sensitivity.Rational cell culture optimization enhances experimental reproducibility in cancer cells.Generation of Dose-Response Curves and Improved IC50s for PARP Inhibitor Nanoformulations.Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma
P2860
Q26780232-7705835B-A6E3-400F-A037-49B678B8A60CQ30985881-8E83515B-AB9A-4BB1-9446-9DD504AB88F6Q33838940-21A793CD-5913-4EDA-AAE9-EE7340ED3CF3Q35429116-D294A645-240E-4464-BBD3-21F874762F99Q35561968-3829EDFA-F062-4C48-9857-7C9A3C83A8EFQ37688617-AF8F81B8-9F52-4BFF-8434-6BA3AD99011BQ38400577-2F767831-1B4B-490A-A86A-D8FD9332DC62Q38628538-AC821C8C-A6D1-4861-B920-2ED5D99A79E4Q38712272-B1466684-1A0F-4927-905E-2B76A926E377Q38729732-C58B5AD3-AC79-4E1C-8184-4577163DB73EQ38812641-FF749A98-E799-49B8-B556-618D1792CE3BQ38904862-C57D1C20-2252-42BA-90E7-07A6BD090D20Q39018410-146157BD-A1B5-4193-BC6F-52E4BBBF348AQ40153764-0F154F57-064E-4CE5-82F3-307448F0EC4AQ41589116-1886BE19-1E0E-4070-9AA0-F2F198F01E86Q42635307-ED99371F-6B68-4540-8630-E56869713D6DQ47134581-7AF1223F-CFBB-4D5A-957E-B8FF76123D63Q47655442-2917DDF0-EBC9-4C9F-8857-AF5391AF081EQ50315694-527F5BB0-1AF9-4A7B-A251-21A37EAED35AQ50917719-2F82F38D-7164-47A2-A69C-60BF1986AAE4Q57270689-3870900D-97B6-4097-941E-658277B90546
P2860
Enhancing reproducibility in cancer drug screening: how do we move forward?
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Enhancing reproducibility in cancer drug screening: how do we move forward?
@ast
Enhancing reproducibility in cancer drug screening: how do we move forward?
@en
type
label
Enhancing reproducibility in cancer drug screening: how do we move forward?
@ast
Enhancing reproducibility in cancer drug screening: how do we move forward?
@en
prefLabel
Enhancing reproducibility in cancer drug screening: how do we move forward?
@ast
Enhancing reproducibility in cancer drug screening: how do we move forward?
@en
P2093
P2860
P50
P1433
P1476
Enhancing reproducibility in cancer drug screening: how do we move forward?
@en
P2093
Andrew H Beck
David F Stem
Leming Shi
P2860
P304
P356
10.1158/0008-5472.CAN-14-0725
P407
P50
P577
2014-07-11T00:00:00Z